Study of BMS-986012 in Subjects With Small Cell Lung Caner
Phase 1
- Conditions
- Small Cell Lung Cancer
- Registration Number
- JPRN-jRCT2080223369
- Lead Sponsor
- Bristol-Myers Squibb K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Histological or cytological confirmed small cell lung cancer (SCLC)
Eastern Cooperative Oncology Group Performance Status 0-1
at least one measurable lesion that is not amenable to resection.
Adequate organ function
Exclusion Criteria
Symptomatic central nervous system (CNS) metastases
Greater than or equal to Grade 2 peripheral neuropathy
Uncontrolled or significant cardiac disease
Active or chronic infection with Human Immunodeficiency Virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method